These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 21109406)

  • 1. Costs of illness and care in Parkinson's disease.
    Korczyn AD
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):151-2. PubMed ID: 21109406
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indirect costs in idiopathic Parkinson's disease].
    Barth F; Baum B; Bremen D; Meuser T; Jost WH
    Fortschr Neurol Psychiatr; 2005 Apr; 73(4):187-91. PubMed ID: 15806436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost and quality aspects in the treatment of Parkinson's disease].
    Müller T; Dodel R; Fritze J
    Z Arztl Fortbild Qualitatssich; 2006; 100(4):291-5. PubMed ID: 16878798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.
    Müller T; Voss B; Hellwig K; Przuntek H
    NeuroRehabilitation; 2003; 18(3):271-5. PubMed ID: 14530592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increasing societal costs of Parkinson disease and Alzheimer disease. Aging population and medical progress yield more and more expensive care].
    Lökk J
    Lakartidningen; 2011 Nov 23-29; 108(47):2422-3. PubMed ID: 22468382
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the cost of Parkinson's disease.
    McCrone P; Allcock LM; Burn DJ
    Mov Disord; 2007 Apr; 22(6):804-12. PubMed ID: 17290462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evidence in Parkinson's disease: a review.
    Lindgren P
    Eur J Health Econ; 2004 Oct; 5 Suppl 1():S63-6. PubMed ID: 15754076
    [No Abstract]   [Full Text] [Related]  

  • 15. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
    Davis KL; Edin HM; Allen JK
    Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of illness in Parkinson's disease.
    Huse DM; Schulman K; Orsini L; Castelli-Haley J; Kennedy S; Lenhart G
    Mov Disord; 2005 Nov; 20(11):1449-54. PubMed ID: 16007641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.